Syntropharma Ltd.
This article was originally published in Start Up
Executive Summary
Syntropharma Ltd. aims to take known drugs that can be improved via transdermal delivery, or gain product life-extension through reformulation in the novel delivery mechanism. The company is focusing on two candidates: a transdermal selegiline patch for depression (aimed at the European market) and a patch formulation of naltrexone, an opioid receptor antagonist for battling dependence on alcohol and opiates.
You may also be interested in...
Start-Up Previews (03/2010)
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, Transdermal Drug Delivery: More Than Skin Deep, features profiles of AllTranz, Ocelus, Quinnova and Syntropharma. Plus these Start-Ups Across Health Care: Apnex Medical, Cellular Dynamics, Helix Therapeutics, Presym and Vatrix Medical.
Ocelus Ltd.
Ocelus Ltd. hopes to extend transdermal delivery to macromolecules. Its early-stage technology combines a microchip reservoir with microneedles that could painlessly inject precise yet tiny amounts of a drug into the skin at hundreds of sites per square centimeter. This could make administration simpler, and by reducing the pain associated with injectable drugs, improve patient compliance.
AllTranz Inc.
AllTranz Inc. has technology suitable for making pro-drugs out of opioids and cannabinoids, and it thinks these can be developed as treatments for a wide range of indications, from neuropathic pain to addiction, pancreatitis, and more. The company is leading, however, with a gel formulation that combines cannabidiol and penetration enhancers to treat the pain of osteoarthritis as well as strains and sprains.